FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980977098> ?p ?o ?g. }

• W2980977098 endingPage "10" @default.
• W2980977098 startingPage "1" @default.
• W2980977098 abstract "Padsevonil is an antiepileptic drug (AED) candidate synthesized in a medicinal chemistry program initiated to rationally design compounds with high affinity for synaptic vesicle 2 (SV2) proteins and low-to-moderate affinity for the benzodiazepine binding site on GABAA receptors. The pharmacological profile of padsevonil was characterized in binding and electrophysiological experiments. At recombinant SV2 proteins, padsevonil's affinity for SV2A was greater than that of levetiracetam and brivaracetam (pKi 8.5, 5.2, and 6.6, respectively). Unlike the latter AEDs, both selective SV2A ligands, padsevonil also displayed high affinity for the SV2B and SV2C isoforms (pKi 7.9 and 8.5, respectively). Padsevonil's interaction with SV2A differed from that of levetiracetam and brivaracetam; it exhibited slower binding kinetics: dissociation t1/2 30 minutes from the human protein at 37°C compared with <0.5 minute for levetiracetam and brivaracetam. In addition, its binding was not potentiated by the allosteric modulator UCB1244283. At recombinant GABAA receptors, padsevonil displayed low to moderate affinity (pIC50≤6.1) for the benzodiazepine site, and in electrophysiological studies, its relative efficacy compared with zolpidem (full-agonist reference drug) was 40%, indicating partial agonist properties. In in vivo (mice) receptor occupancy studies, padsevonil exhibited SV2A occupancy at low ED50 (0.2 mg/kg) and benzodiazepine site occupancy at higher doses (ED50 36 mg/kg), supporting in vitro results. Padsevonil's selectivity for its intended targets was confirmed in profiling studies, where it lacked significant effects on a wide variety of ion channels, receptors, transporters, and enzymes. Padsevonil is a first-in-class AED candidate with a unique target profile allowing for presynaptic and postsynaptic activity. SIGNIFICANCE STATEMENT: Padsevonil is an antiepileptic drug candidate developed as a single molecular entity interacting with both presynaptic and postsynaptic targets. Results of in vitro and in vivo radioligand binding assays confirmed this target profile: padsevonil displayed nanomolar affinity for the three synaptic vesicle 2 protein isoforms (SV2A, B, and C) and micromolar affinity for the benzodiazepine binding site on GABAA receptors. Furthermore, padsevonil showed greater affinity for and slower binding kinetics at SV2A than the selective SV2A ligands, levetiracetam, and brivaracetam." @default.
• W2980977098 created "2019-10-25" @default.
• W2980977098 creator A5005377294 @default.
• W2980977098 creator A5039650196 @default.
• W2980977098 creator A5058041579 @default.
• W2980977098 creator A5075556991 @default.
• W2980977098 creator A5087482611 @default.
• W2980977098 creator A5090649309 @default.
• W2980977098 date "2019-10-16" @default.
• W2980977098 modified "2023-10-14" @default.
• W2980977098 title "Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABA_A Receptor" @default.
• W2980977098 cites W1504181864 @default.
• W2980977098 cites W1505043869 @default.
• W2980977098 cites W1534865669 @default.
• W2980977098 cites W1576738253 @default.
• W2980977098 cites W1943229448 @default.
• W2980977098 cites W1968626495 @default.
• W2980977098 cites W1984209762 @default.
• W2980977098 cites W1993009709 @default.
• W2980977098 cites W2003338471 @default.
• W2980977098 cites W2011096544 @default.
• W2980977098 cites W2011652334 @default.
• W2980977098 cites W2013775967 @default.
• W2980977098 cites W2028095154 @default.
• W2980977098 cites W2028633253 @default.
• W2980977098 cites W2029085177 @default.
• W2980977098 cites W2032794571 @default.
• W2980977098 cites W2037655028 @default.
• W2980977098 cites W2038552386 @default.
• W2980977098 cites W2039108005 @default.
• W2980977098 cites W2039779597 @default.
• W2980977098 cites W2047978949 @default.
• W2980977098 cites W2050393788 @default.
• W2980977098 cites W2065922695 @default.
• W2980977098 cites W2074631079 @default.
• W2980977098 cites W2079669581 @default.
• W2980977098 cites W2083198897 @default.
• W2980977098 cites W2083702687 @default.
• W2980977098 cites W2086126018 @default.
• W2980977098 cites W2095271866 @default.
• W2980977098 cites W2122573606 @default.
• W2980977098 cites W2127801604 @default.
• W2980977098 cites W2130673921 @default.
• W2980977098 cites W2163639807 @default.
• W2980977098 cites W2221351417 @default.
• W2980977098 cites W2232966793 @default.
• W2980977098 cites W2284268250 @default.
• W2980977098 cites W2289032146 @default.
• W2980977098 cites W2468320587 @default.
• W2980977098 cites W2474320719 @default.
• W2980977098 cites W2539233923 @default.
• W2980977098 cites W2562398824 @default.
• W2980977098 cites W2606262357 @default.
• W2980977098 cites W2614237850 @default.
• W2980977098 cites W2778879042 @default.
• W2980977098 cites W2980527401 @default.
• W2980977098 doi "https://doi.org/10.1124/jpet.119.261149" @default.
• W2980977098 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31619465" @default.
• W2980977098 hasPublicationYear "2019" @default.
• W2980977098 type Work @default.
• W2980977098 sameAs 2980977098 @default.
• W2980977098 citedByCount "20" @default.
• W2980977098 countsByYear W29809770982019 @default.
• W2980977098 countsByYear W29809770982020 @default.
• W2980977098 countsByYear W29809770982021 @default.
• W2980977098 countsByYear W29809770982022 @default.
• W2980977098 countsByYear W29809770982023 @default.
• W2980977098 crossrefType "journal-article" @default.
• W2980977098 hasAuthorship W2980977098A5005377294 @default.
• W2980977098 hasAuthorship W2980977098A5039650196 @default.
• W2980977098 hasAuthorship W2980977098A5058041579 @default.
• W2980977098 hasAuthorship W2980977098A5075556991 @default.
• W2980977098 hasAuthorship W2980977098A5087482611 @default.
• W2980977098 hasAuthorship W2980977098A5090649309 @default.
• W2980977098 hasBestOaLocation W29809770981 @default.
• W2980977098 hasConcept C166342909 @default.
• W2980977098 hasConcept C168258287 @default.
• W2980977098 hasConcept C169760540 @default.
• W2980977098 hasConcept C170493617 @default.
• W2980977098 hasConcept C185592680 @default.
• W2980977098 hasConcept C2776038425 @default.
• W2980977098 hasConcept C2777332695 @default.
• W2980977098 hasConcept C2778173252 @default.
• W2980977098 hasConcept C2778186239 @default.
• W2980977098 hasConcept C2778938600 @default.
• W2980977098 hasConcept C55493867 @default.
• W2980977098 hasConcept C86803240 @default.
• W2980977098 hasConcept C98274493 @default.
• W2980977098 hasConceptScore W2980977098C166342909 @default.
• W2980977098 hasConceptScore W2980977098C168258287 @default.
• W2980977098 hasConceptScore W2980977098C169760540 @default.
• W2980977098 hasConceptScore W2980977098C170493617 @default.
• W2980977098 hasConceptScore W2980977098C185592680 @default.
• W2980977098 hasConceptScore W2980977098C2776038425 @default.
• W2980977098 hasConceptScore W2980977098C2777332695 @default.
• W2980977098 hasConceptScore W2980977098C2778173252 @default.
• W2980977098 hasConceptScore W2980977098C2778186239 @default.
• W2980977098 hasConceptScore W2980977098C2778938600 @default.

• next